Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

PIK3CA mutation + HR positive

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

2099; 5290; 5241

Related biomarkers:

‹

›

PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	alpelisib Sensitive: A1 - Approval alpelisib Sensitive : A1	alpelisib Sensitive: A1 - Approval alpelisib Sensitive : A1
PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	CDK6 inhibitor + alpelisib Sensitive: A2 - Guideline CDK6 inhibitor + alpelisib Sensitive : A2	CDK6 inhibitor + alpelisib Sensitive: A2 - Guideline CDK6 inhibitor + alpelisib Sensitive : A2
PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	CDK4 inhibitor + alpelisib Sensitive: A2 - Guideline CDK4 inhibitor + alpelisib Sensitive : A2	CDK4 inhibitor + alpelisib Sensitive: A2 - Guideline CDK4 inhibitor + alpelisib Sensitive : A2
PIK3CA mutation + HR positive	Hormone Receptor Positive Breast Cancer	PIK3CA mutation + HR positive	Hormone Receptor Positive Breast Cancer	alpelisib Sensitive: C1 - Off-label alpelisib Sensitive : C1	alpelisib Sensitive: C1 - Off-label alpelisib Sensitive : C1
PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	GDC-0077 Sensitive: C2 – Inclusion Criteria GDC-0077 Sensitive : C2	GDC-0077 Sensitive: C2 – Inclusion Criteria GDC-0077 Sensitive : C2
PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	palbociclib + GDC-0077 Sensitive: C3 – Early Trials palbociclib + GDC-0077 Sensitive : C3	palbociclib + GDC-0077 Sensitive: C3 – Early Trials palbociclib + GDC-0077 Sensitive : C3
PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	alpelisib + GDC-0032 Sensitive: C3 – Early Trials alpelisib + GDC-0032 Sensitive : C3	alpelisib + GDC-0032 Sensitive: C3 – Early Trials alpelisib + GDC-0032 Sensitive : C3
PIK3CA mutation + HR positive	HER2 Positive Breast Cancer	PIK3CA mutation + HR positive	HER2 Positive Breast Cancer	trastuzumab Resistant: C3 – Early Trials trastuzumab Resistant : C3	trastuzumab Resistant: C3 – Early Trials trastuzumab Resistant : C3
PIK3CA mutation + HR positive	HER2 Positive Breast Cancer	PIK3CA mutation + HR positive	HER2 Positive Breast Cancer	ado-trastuzumab emtansine Sensitive: C3 – Early Trials ado-trastuzumab emtansine Sensitive : C3	ado-trastuzumab emtansine Sensitive: C3 – Early Trials ado-trastuzumab emtansine Sensitive : C3
PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	CDK4 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor Resistant : C3	CDK4 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor Resistant : C3
PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	CDK6 inhibitor Resistant: C3 – Early Trials CDK6 inhibitor Resistant : C3	CDK6 inhibitor Resistant: C3 – Early Trials CDK6 inhibitor Resistant : C3
PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3